Editorial Article
The FASTER Act Did Not Take Sesame Out of American Food — It Took It Out of the Recall Statistics
Two facts that should not both be true
In 2025, 38.8 per cent of all food recalls issued by the US Food and Drug Administration and the US Department of Agriculture were for undeclared allergens. That is the largest single cause of American food recalls by a wide margin, and it is the figure reported by US PIRG’s annual recall tally: 320 recalls in the year, of which undeclared allergens accounted for nearly four in ten.
Now the second fact. In the same period, sesame-only recalls fell. PIRG recorded 13 sesame-only recalls in 2023 and seven in 2024, and its total for allergen recalls fell from 154 in 2023 — nearly half of that year’s recalls — to 101 in 2024, or 34 per cent.
Both of those things are true at once, and taken together they describe the single most instructive episode in modern allergen regulation. Sesame did not leave American food. It left the recall statistics.
What the FASTER Act actually did
The Food Allergy Safety, Treatment, Education, and Research Act made sesame the ninth major food allergen. From 1 January 2023, packaged foods and dietary supplements containing sesame — or an ingredient made from sesame — must declare it as an allergen, either in the ingredient list, in a “Contains” statement, or in parentheses after the ingredient name.
That is a declaration requirement. It says nothing at all about how much sesame is acceptable, and it says nothing about what a manufacturer may say on a precautionary basis. There is no statutory threshold for any allergen in the United States. Allergen advisory statements — the “may contain” line — are not regulated as to level.
So a manufacturer holding a product with a cross-contact risk had two options. Test enough to be confident the line was clean, or declare the allergen and remove the uncertainty. The FDA’s own consumer guidance records which option some of them took, in a sentence that deserves to be quoted in full:
“Some food manufacturers have recently changed their recipes since the FASTER Act went into effect. There are now food products with small amounts of sesame that did not have it before.”
Adding the allergen was cheaper than proving its absence. That is not a compliance failure and it was not unlawful. Under a declaration-only regime it was the rational commercial decision, and it tells you precisely what this market is worth when the alternative to testing is free.
The arithmetic of an allergen recall
The composition of the 2025 allergen recalls explains why this matters commercially. Milk is the most frequent offender by a distance, and milk is usually undeclared in products that were never supposed to contain it — a changeover failure rather than a formulation error. Tree nuts, wheat and egg follow. Sesame, now fully declared, sits at 5.3 per cent.
| Allergen | Share of undeclared-allergen recalls, 2025 |
|---|---|
| Milk | 20.6% |
| Tree nuts | 16.8% |
| Wheat | 7.6% |
| Egg | 6.1% |
| Sesame | 5.3% |
| Multiple allergens in one product | 25.2% |
| Other allergens | 18.4% |
The 25.2 per cent involving several allergens at once is the diagnostic figure. A product that misses one allergen has a labelling or supplier problem. A product that misses several has a changeover or a line-clearance problem, and that is a process control question answered by sampling rather than by reading a specification.
The United Kingdom shows the same pattern more starkly. Food Standards Agency alert data records 85 allergy alerts among 142 recall events in 2025 — roughly 61 per cent of everything recalled, against 55 recalls for microbiological and other safety problems combined. A product that is entirely safe for most of the population is withdrawn from sale because its label omits one of the fourteen allergens European and UK law requires to be declared.
No other failure mode in food manufacturing converts a paperwork error into a public withdrawal at that rate. And no other failure mode is as cheap to prevent with the right test — which is why the absence of a threshold has been so expensive.
What changed in July 2026
The Codex Alimentarius Commission adopted guidelines on precautionary allergen labelling as an annex to the General Standard for the Labelling of Pre-packaged Foods. The annex sets 21 reference doses for IgE-mediated allergy, from 1.0 milligram of total protein for almond, Brazil nut, cashew, pistachio, macadamia, pine nut, walnut, pecan, celery and mustard, up to 200.0 milligrams for crustacea, plus 4.0 milligrams of total gluten for coeliac disease.
The action level is the reference dose divided by the amount of food reasonably expected to be consumed on a single eating occasion. Three consequences follow.
It has a denominator. The same concentration is compliant in a sauce and non-compliant in a bakery product, because the bakery product is eaten in a larger portion. An action level is therefore not a universal number per allergen. It is a number per product, and every product needs its own calculation.
It runs both ways. Precautionary labelling is justified where unintentional presence cannot be mitigated to or below the action level — and should not be used where it can. That is the clause that ends the FASTER Act’s perverse incentive. Once a “may contain” line has to be earned by evidence, adding the allergen to the recipe stops being the cheap option.
It has holes. There is no reference dose for rye, barley, oats, mollusc or sulphite, and the annex leaves national competent authorities to set one consistent with recognised principles. Every gap becomes a market-by-market difference, and a company selling into twelve countries holds twelve calculations rather than one.
The gluten contradiction, and why it retires a labelling position
The sharpest illustration of why this cannot be treated as a look-up is gluten. The annex sets a reference dose of 4.0 milligrams of total gluten, expressed as a dose. European law permits the term “gluten-free” where gluten does not exceed 20 milligrams per kilogram, under Commission Implementing Regulation (EU) No 828/2014, expressed as a concentration.
A dose and a concentration are not comparable quantities, and the annex says so directly: whether “gluten-free” may be used requires both parameters to be considered together. It then adds a rule with immediate commercial effect — where a precautionary statement for wheat, barley or rye is necessary, the term “gluten-free” must not be used at all.
A product cannot be simultaneously gluten-free and carrying a may-contain for gluten. That retires a position a number of brands currently occupy, and it makes the gluten-free products market the first category where the new arithmetic has to be worked through product by product. Every unit sold under a gluten-free claim is an analytical result before it is a marketing position.
Where it is still unresolved
| Jurisdiction | Allergens requiring declaration | Precautionary labelling | Quantitative basis |
|---|---|---|---|
| Codex (international reference) | 8 food groups in CXC 80-2020; 21 reference doses in the 2026 annex | Permitted above the action level, discouraged below it | Reference dose ÷ portion consumed |
| European Union | 14 under Regulation (EU) No 1169/2011, Annex II | Not harmonised across member states | 20 mg/kg for gluten-free claims under Reg. (EU) No 828/2014 |
| United States | 9 major allergens, sesame since 1 January 2023 | Allergen advisory statements, not regulated as to level | None statutory |
| United Kingdom | 14, plus labelling for non-prepacked food | Food Standards Agency position on criteria published | Threshold levels within the FSA position |
Three things to watch. European legislation to harmonise precautionary labelling is listed for consideration in the fourth quarter of 2027 — a consultation timetable, not a statute. The FDA met on allergen thresholds in February 2026 and has published no rule, so the American position that produced the sesame episode remains open. And the Codex annex is an international reference text: it binds nobody until a national authority adopts it.
What is settled is the direction. A threshold prices the alternative to testing, and the alternative to testing was, until 2026, free.
What this means for the people who sell the tests
The commercial consequence runs through the whole supply chain. Neogen, R-Biopharm, Romer Labs, Thermo Fisher Scientific and Bio-Rad Laboratories sell the kits and devices that produce the result. Eurofins Scientific, SGS, Bureau Veritas, Intertek Group and Mérieux NutriSciences sell the accredited confirmation and the report a retailer will accept. Neither group sells the thing the annex actually demands, which is the documented reasoning behind a labelling decision.
That layer — risk assessment, action-level derivation, label review, supplier verification and retained records — is the fastest-growing part of the market. In the full market analysis it is sized at USD 105 million in 2025, growing at 14.95 per cent against 7.09 per cent for testing, to reach USD 320 million by 2033. It is the only component where price rises.
The categories that will feel it first are the ones where cross-contact is structural rather than incidental: cookies and chocolate, where nuts, milk and wheat share lines; dairy, where milk is the most frequently undeclared allergen of all; and plant-based meat, where soy, wheat and legume are the formulation rather than a contaminant. All of them sit under Food Safety and Quality Testing.
The lesson from sesame is the one to carry: a regime that demands declaration without defining a threshold does not remove an allergen from the food supply. It relocates the allergen into the ingredient list and out of the recall statistics, and it makes the absence of a number the most expensive thing in the system.
References
- US Food and Drug Administration. The FASTER Act: Sesame Is the Ninth Major Food Allergen; and “Allergic to Sesame? Food Labels Now Must List Sesame as an Allergen”.
- US PIRG Education Fund. Annual food recall tallies, 2023–2025 editions, including recall-cause shares and allergen recall counts.
- Food Standards Agency. Food alert records, allergy alerts and recall events, 2025.
- Codex Committee on Food Labelling, 49th session. Annex to CXS 1-1985: Guidelines on the use of precautionary allergen labelling, reference dose tables 4.3.1 and 4.3.2.
- Codex Alimentarius Commission. Code of Practice on Food Allergen Management for Food Business Operators, CXC 80-2020.
- Regulation (EU) No 1169/2011, Annex II; Commission Implementing Regulation (EU) No 828/2014.
Frequently Asked Questions
How many US food recalls are caused by undeclared allergens?
38.8 per cent of the 320 American food recalls issued by the FDA and USDA in 2025 were for undeclared allergens, making it the largest single cause by a wide margin. Within those, milk accounted for 20.6 per cent, tree nuts 16.8, wheat 7.6, egg 6.1 and sesame 5.3, with 25.2 per cent involving several allergens in one product. The figures come from US PIRG's annual food recall tally.
Why did sesame recalls fall after the FASTER Act?
Because a declaration requirement with no threshold made adding the allergen cheaper than proving its absence. The FDA's own consumer guidance records that some manufacturers changed their recipes after the FASTER Act took effect, and that there are now products containing small amounts of sesame that did not contain it before. The allergen did not leave the food; it moved from undeclared to declared, and therefore out of the recall statistics.
Why does the July 2026 Codex annex change the incentive?
Because it sets 21 reference doses and defines an action level as the reference dose divided by the amount of food reasonably consumed at a single eating occasion. Precautionary labelling is justified above that level and should not be used below it. The second half is the change that matters: a 'may contain' statement now has to be earned by evidence, so a manufacturer can no longer discharge the risk by adding the allergen to the recipe.
Can a product be gluten-free and still carry a may-contain statement for wheat?
Under the annex, 4.0 milligrams of total gluten is a reference dose, while the 20 milligrams per kilogram used for the European gluten-free claim under Regulation (EU) No 828/2014 is a concentration. The two are different quantities and cannot be compared directly. The annex also provides that where a precautionary statement for wheat, barley or rye is necessary, the term 'gluten-free' must not be used — so a product cannot be simultaneously gluten-free and carrying a may-contain for gluten.
